Secondary Prevention After a Heart Attack in Women: The Care Gap That Starts at Discharge

A woman has a heart attack. She is admitted, treated, discharged with a prescriptions list, and told to follow up. What happens in the following twelve months determines whether she has another one. And at every step in that chain — prescription at discharge, referral to cardiac rehabilitation, adherence at six months, depression screening, lipid target achievement — women consistently fare worse than men. Not because the evidence-based treatments work differently in women. They do not. But because the secondary prevention system has been built around a default patient that was not her.

This article is about what secondary prevention requires after a cardiac event, where the evidence-to-practice gap is widest for women, and what a woman emerging from a cardiac event should expect and push for.

What Secondary Prevention Is

Secondary prevention is the set of interventions applied after a confirmed cardiovascular event to prevent a second one. Unlike primary prevention — which focuses on reducing risk in people who have not yet had an event — secondary prevention operates in a population with established disease and documented elevated risk.

The core of secondary prevention is pharmacological and behavioral: aggressive lipid reduction with high-intensity statins, antiplatelet therapy to reduce clot formation, blood pressure control, and structured exercise rehabilitation. These interventions reduce the risk of recurrent MI, stroke, hospitalization for heart failure, and cardiovascular death. They are not optional recommendations. They are the evidence base.

For women specifically, secondary prevention carries one additional dimension that does not appear in the men’s framework in the same way: the baseline from which a woman enters secondary prevention is often different. The MINOCA problem, the higher prevalence of microvascular disease, the post-event depression differential, and the unique medication tolerability pattern all modify how the secondary prevention protocol needs to be calibrated for women.

The Prescription Gap at Discharge

The largest, most documented gap in women’s secondary prevention begins the moment of hospital discharge. Multiple registry studies have established that women discharged after MI are prescribed high-intensity statins, ACE inhibitors, and P2Y12 inhibitors at rates 5 to 12 percent lower than men, even after controlling for clinical severity, age, and comorbidity.

The American Heart Association’s Get With The Guidelines registry, which captures data from hundreds of US hospitals, has consistently documented these sex differences in discharge prescribing over more than a decade. The NCDR ACTION registry, with over 250,000 STEMI patients, shows women are less likely to receive guideline-directed therapy despite presenting with similar infarct characteristics.

The reasons are complex and partially reflect legitimate clinical differences — women have higher bleeding risk on dual antiplatelet therapy, higher rates of renal impairment requiring ACE inhibitor dose adjustment, and higher rates of statin myalgia requiring dose optimization. These are real considerations. What is not acceptable is treating those considerations as reasons to undertreater rather than to manage more carefully.

High-Intensity Statins: What Women Need to Know About Myalgia

High-intensity statin therapy — rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg — is the lipid foundation of secondary prevention for everyone with established cardiovascular disease. The LDL target after an event is below 70 mg/dL, with an ApoB target below 55 mg/dL for very high-risk patients.

Women have higher rates of statin-associated muscle symptoms than men in observational data — estimates range from 1.5 to 2 times the rate in men, though randomized trial data show a smaller difference. The mechanisms are not fully established but likely involve lower muscle mass, vitamin D deficiency (which is more common in women), and pharmacokinetic sex differences in statin metabolism.

Statin myalgia does not mean statins cannot be used. It means the approach requires adjustment: using a lower starting dose, choosing a statin with a better tolerability profile (rosuvastatin and pravastatin have relatively favorable muscle symptom profiles), ensuring adequate vitamin D levels before initiating, and distinguishing true myopathy (with elevated CK) from mild discomfort. Stopping statins because of myalgia and not restarting is a cardiovascular risk management failure. The conversation should always be about finding the tolerable regimen, not about abandoning lipid reduction.

The MINOCA Problem in Secondary Prevention

MINOCA — myocardial infarction with non-obstructive coronary arteries — affects 6 to 15 percent of women presenting with MI, compared to 1 to 3 percent of men. Women with MINOCA have elevated troponin, typical ischemic ECG changes or wall motion abnormalities on echo, but no large coronary artery occlusion on angiography.

The mechanisms are heterogeneous: plaque erosion without complete occlusion, coronary artery spasm, microvascular thrombosis, Takotsubo cardiomyopathy, dissection, or spontaneous coronary artery dissection. Each mechanism may call for a different therapeutic approach. All require active secondary prevention.

The secondary prevention gap is particularly pronounced in MINOCA. A woman who has a heart attack and is shown a normal-looking angiogram is frequently told some version of “your arteries are fine.” This statement, while technically referring to macroscopic plaque burden, is clinically misleading. MINOCA carries real recurrence risk — five-year major adverse cardiovascular event rates in MINOCA approach those of obstructive MI in some series. Women with MINOCA who do not receive secondary prevention pharmacotherapy are not protected; they are inadequately treated.

After MINOCA, the workup should include cardiac MRI (to assess myocardial injury patterns and look for myocarditis or Takotsubo), comprehensive laboratory testing, and, when mechanism is unclear, invasive coronary function testing (coronary flow reserve, acetylcholine provocation testing for spasm). The secondary prevention regimen is then tailored to the most likely mechanism.

Cardiac Rehabilitation: Enrollment, Dropout, and What Changes Outcomes

Cardiac rehabilitation is a structured program of medically supervised exercise, dietary counseling, and psychosocial support administered after a cardiac event. The cardiovascular evidence base is strong: participation in cardiac rehabilitation reduces all-cause mortality by 20 to 25 percent and cardiovascular mortality by 26 percent in observational studies. The magnitude of benefit is comparable in women and men.

Women are referred to cardiac rehabilitation at consistently lower rates. An analysis of Medicare data found women had referral rates 15 to 22 percent lower than men after MI. Women who are referred complete fewer sessions — the average completion for women in multiple US programs is 12 to 16 sessions, compared to 24 to 36 sessions in men.

The barriers are documented and specific. Women cite transportation access more frequently than men. Women carry disproportionate caregiving obligations — for children, aging parents, or partners — that create scheduling conflicts. Women are more likely to report that they felt their physician did not explicitly recommend rehabilitation, only mentioned it. And women describe feeling like the “odd one out” in rehabilitation programs predominantly attended by older men.

Some programs have documented improved women’s enrollment and completion rates with targeted interventions: home-based rehabilitation options, mixed-sex group sessions with peer support, and explicit female-directed language in the program structure. These modifications do not change the medicine; they change the access.

If your physician does not explicitly refer you to cardiac rehabilitation after an event, ask for the referral. If the program is not accessible, ask about home-based alternatives. The clinical benefit of cardiac rehabilitation is too large to lose to a logistics barrier.

Post-MI Depression in Women: A Cardiovascular Risk Factor

The prevalence of depression in the first year after MI is approximately 15 to 20 percent in men and 25 to 40 percent in women. Post-MI depression is not a psychiatric comorbidity separate from the cardiovascular disease; it is integrated with it through behavioral and neurobiological pathways.

Depression predicts medication non-adherence. Women with post-MI depression fill their statin and antiplatelet prescriptions at significantly lower rates at six and twelve months. Depression predicts cardiac rehabilitation dropout — among women who are enrolled, those with untreated depression complete 40 to 60 percent fewer sessions than those without. Depression predicts recurrent cardiovascular events — the adjusted hazard ratio for mortality in post-MI depression in women is 1.5 to 2.5 in several prospective cohort studies.

Depression after a heart attack in a woman is not simply a psychological response to a frightening event. It is a physiological state with documented links to sympathetic nervous system activation, inflammatory cytokine elevation, platelet hyper-reactivity, and impaired heart rate variability — all mechanisms that increase cardiovascular risk. Treating post-MI depression is treating cardiovascular disease.

Systematic depression screening at the post-MI follow-up visit (typically using the PHQ-2 or PHQ-9) should be standard. When depression is identified, treatment should begin promptly — selective serotonin reuptake inhibitors (SSRIs) have an acceptable cardiac safety profile post-MI, and behavioral interventions including cardiac rehabilitation participation have antidepressant effects. Tricyclic antidepressants and bupropion are generally avoided in the early post-MI period due to QT prolongation and seizure threshold effects respectively.

Dual Antiplatelet Therapy: Bleeding Risk and Duration

After MI or coronary intervention with stenting, dual antiplatelet therapy (DAPT) — typically aspirin plus a P2Y12 inhibitor such as clopidogrel, ticagrelor, or prasugrel — is recommended to reduce recurrent clot formation in the treated vessel. The standard duration is twelve months for ACS patients, shorter in patients at elevated bleeding risk with drug-eluting stents.

Women have a higher absolute bleeding risk on DAPT than men — higher rates of gastrointestinal bleeding and procedural access-site complications after cardiac catheterization. This real difference in bleeding risk is a legitimate clinical consideration in DAPT selection and duration. However, in clinical practice, the bleeding risk consideration is sometimes used to justify complete avoidance of appropriate antiplatelet therapy rather than careful dose and duration selection.

The correct approach is individualized DAPT selection (clopidogrel has lower bleeding risk than ticagrelor; prasugrel is generally avoided in women with low body weight), proton pump inhibitor co-prescription to reduce GI bleeding risk, and duration decisions made through structured bleeding-ischemia tradeoff calculation (tools like the PRECISE-DAPT score). Blanket avoidance of antiplatelet therapy in women because of bleeding concern results in higher rates of in-stent thrombosis and recurrent MI.

Blood Pressure After an Event

Hypertension after a cardiac event requires control in women as in men. The target is below 130/80 mmHg per the 2017 ACC/AHA guidelines for secondary prevention. ACE inhibitors and ARBs are preferred agents when left ventricular dysfunction or diabetes is present, as they confer direct cardioprotection beyond blood pressure reduction.

Women metabolize several antihypertensive agents differently. ACE inhibitors cause cough at higher rates in women — estimates range from twice to four times as common as in men. ARBs do not carry the same cough risk and are appropriate substitutions. Thiazide diuretics can cause hyponatremia at higher rates in older women. These tolerability differences are reasons to match the agent to the individual, not reasons to defer blood pressure treatment.

Post-MI women also frequently have white-coat hypertension — blood pressure elevated in the clinical setting but normal at home — which can lead to overtreatment. Home blood pressure monitoring is a useful tool for accurate blood pressure assessment and dose adjustment in women who have had a cardiac event.

The Adherence Cliff at Six Months

Secondary prevention fails most visibly not at prescribing but at adherence. Multiple registry studies document a sharp drop in medication adherence between hospital discharge and six-month follow-up in women — sharper than the equivalent drop in men.

The PURE study (Prospective Urban Rural Epidemiology), which followed cardiovascular patients across 17 countries, found that medication adherence in women with established CVD was substantially lower than in men at two-year follow-up across high-, middle-, and low-income countries. The pattern is not confined to resource-limited settings. US data from pharmacy claims show that women are more likely to have gaps in statin fills, antiplatelet fills, and beta-blocker fills in the year following a cardiac event than men of equivalent age and clinical severity.

The mechanisms are overlapping: depression (documented above), cost barriers (women have lower income and greater out-of-pocket medication expenditure in some age groups), family caregiving that disrupts self-care routines, and the persistent framing — by patients and sometimes by physicians — of cardiac disease as something that happened rather than something that requires ongoing treatment. The woman who has a heart attack and is told to “take it easy and follow up in three months” receives a different implicit message than the one who is told “your medication is preventing the next event and missing a dose matters.”

Framing secondary prevention explicitly as ongoing treatment — not recovery — changes adherence. In intervention programs that emphasized this framing with specific coaching, medication adherence at twelve months in women improved significantly. The clinical content of the conversation at discharge matters.

What to Do This Week

If you have had a heart attack, coronary intervention, or have been told you have established coronary artery disease, review your current medication regimen against the secondary prevention framework. You should have, at minimum: a high-intensity statin, antiplatelet therapy (aspirin, and a P2Y12 inhibitor if you had a stent or ACS within the past year), blood pressure medication if your BP is above 130/80 mmHg, and a beta-blocker if your left ventricular function is reduced.

If you have not been referred to cardiac rehabilitation, request it explicitly. The referral often has to be physician-initiated for insurance coverage. The conversation at your next follow-up visit should include cardiac rehab enrollment, lipid target confirmation, blood pressure measurement, and depression screening.

If you had a heart attack and were told your arteries were “fine” — if the angiogram showed no blockages — you may have had MINOCA. Ask your physician whether you had a cardiac MRI after the event, what secondary prevention medications are appropriate for your specific mechanism, and whether coronary function testing is indicated. A normal angiogram after a heart attack does not mean no secondary prevention is needed.